ATYR Lawsuit: Hagens Berman Urges Atyr Pharma Investors To Act By Dec. 8 Deadline In Suit Over Trial Failure

2025-12-02 05:31:08

(MENAFN- GlobeNewsWire - Nasdaq) Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs' rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit filed against aTyr Pharma, Inc. (NASDAQ: ATYR). The litigation follows a catastrophic 83% single-day stock collapse after the company's flagship drug trial failed to meet its primary endpoint.

The lawsuit alleges that aTyr and its executives provided materially false and misleading information about the efficacy of its drug, Efzofitimod, leading investors to purchase stock at artificially inflated prices.

“In biotech securities cases, the core issue is often whether the company was accurately representing its data and trial design,” said Reed Kathrein“The suit alleges that aTyr concealed material adverse facts concerning Efzofitimod's capability to allow a patient to completely taper their steroid usage-a key measure of efficacy-while emphasizing a multi-billion-dollar market. We are scrutinizing whether these prior statements about the drug's prospects crossed the line into securities law violations. The firm urges investors in aTyr who suffered significant losses to submit your losses now

Legal Analysis: The Clinical Trial Disclosure Gap

Hagens Berman's investigation and the underlying complaint focus on the alleged gap between the company's optimistic public statements and the undisclosed reality of the drug's performance in the Phase 3 EFZO-FIT study.

Key Trial Metric	Allegation & Disclosure	Legal Focus for Investors
Primary Endpoint	Failed to meet the primary endpoint: change from baseline in mean daily oral corticosteroid (OCS) dose.	Whether the company misrepresented the drug's true ability to help patients reduce steroid dependency.
Efficacy Concealment	Allegedly concealed adverse facts about the drug's capability to allow a patient to completely taper off steroids, a core measure of success.	Whether optimistic pronouncements about the drug were misleading given the alleged deficiencies in performance or trial design.
Market Impact	Stock fell from $6.03 to $1.02 (83.2% loss) on September 15, 2025.	Whether investors are entitled to damages resulting from the defendants' alleged wrongful acts and omissions.

Next Steps: Contact Hagens Berman Today

Hagens Berman has a proven track record of securing more than $2.9 billion in settlements for investors in this area of law.

The firm is advising investors who purchased ATYR shares during the Class Period (November 7, 2024, through September 12, 2025) and suffered substantial losses due to the undisclosed trial flaws. The Lead Plaintiff Deadline is December 8, 2025.

TO SUBMIT YOUR ATYR STOCK LOSSES NOW, PLEASE USE THE SECURE FORM BELOW:

Submit your aTyr Pharma (ATYR) Stock Losses
Contact: Reed Kathrein at 844-916-0895 or email ...

Investors may also read more about the investigation here: The Stakes of Clinical Trials: Why Pharma Companies Must Be Accurate and How it Relates to the aTyr Investigation. Or visit the case page here:

If you'd like answers to frequently asked questions about the aTyr case and our investigation, read more )

Whistleblowers: Persons with non-public information regarding aTyr should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ....

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895

MENAFN02122025004107003653ID1110427768

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.